title: Restoration of the Dopamine Transporter through Cell Therapy Improves Dyskinesia in a Rat Model of Parkinson's Disease.
abstract: The dyskinesia of Parkinson's Disease is most likely due to excess levels of dopamine in the striatum. The mechanism may be due to aberrant synthesis but also, a deficiency or absence of the Dopamine Transporter. In this study we have examined the proposition that reinstating Dopamine Transporter expression in the striatum would reduce dyskinesia. We transplanted c17.2 cells that stably expressed the Dopamine Transporter into dyskinetic rats. There was a reduction in dyskinesia in rats that received grafts expressing the Dopamine Transporter. Strategies designed to increase Dopamine Transporter in the striatum may be useful in treating the dyskinesia associated with human Parkinson's Disease.
authors.affiliation: Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Australia, 3010.
authors.forename: D
authors.initials: D
authors.lastname: Tomas
authors.affiliation: Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Australia, 3010.
authors.forename: D
authors.initials: D
authors.lastname: Stanic
authors.affiliation: Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Australia, 3010.
authors.forename: H K
authors.initials: HK
authors.lastname: Chua
authors.affiliation: Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Australia, 3010.
authors.forename: K
authors.initials: K
authors.lastname: White
authors.affiliation: Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Australia, 3010.
authors.forename: W C
authors.initials: WC
authors.lastname: Boon
authors.affiliation: Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Australia, 3010.|Department of Medicine, University of Melbourne, St Vincent's Hospital, Fitzroy, Victoria, Australia, 3065.
authors.forename: M
authors.initials: M
authors.lastname: Horne
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000378:metabolism / Q000473:pathology; D002460:Cell Line; D064987:Cell- and Tissue-Based Therapy; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D050483:Dopamine Plasma Membrane Transport Proteins / Q000235:genetics / Q000378:metabolism*; D004409:Dyskinesia, Drug-Induced / Q000209:etiology / Q000378:metabolism / Q000628:therapy; D007980:Levodopa / Q000008:administration & dosage / Q000494:pharmacology; D008297:Male; D051379:Mice; D058953:Neural Stem Cells / Q000166:cytology / Q000378:metabolism / Q000637:transplantation*; D016627:Oxidopamine / Q000633:toxicity; D010300:Parkinson Disease / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D051381:Rats; D017208:Rats, Wistar
chemical_list: D050483:Dopamine Plasma Membrane Transport Proteins; D007980:Levodopa; D016627:Oxidopamine; D004298:Dopamine